PATENT CLAIM ANALYSIS

Application Number: 16383026
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-10
Patent Classification: ["514", "307000"]

Abstract:
The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.

Claim (Index 13):
The method of  claim 11 , wherein the second amount is about 130 mg/m 2 .

Metadata:
- Claim Count in Document: 50.0
- Percentile: 100.0
- Lexical Diversity: 1.47917
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10794383', '12436697', '11520479', '14959497', '10800990']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7663102179702694
- 35 USC 102 Novelty (BERT): 0.5149923430917148
- Combined Prediction Score: 0.7411784304824139
- Mean Citation Score: 240.8671
- Max Citation Score: 266.61502
- Similarity Product: 166.0846848463047

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test